Swiss National Bank grew its holdings in shares of Homology Medicines Inc (NASDAQ:FIXX) by 56.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,200 shares of the company’s stock after acquiring an additional 13,000 shares during the period. Swiss National Bank’s holdings in Homology Medicines were worth $708,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of FIXX. Bank of America Corp DE grew its stake in shares of Homology Medicines by 7.1% in the 4th quarter. Bank of America Corp DE now owns 30,439 shares of the company’s stock valued at $681,000 after buying an additional 2,027 shares during the period. BNP Paribas Arbitrage SA acquired a new stake in shares of Homology Medicines in the 1st quarter valued at about $99,000. Spark Investment Management LLC acquired a new stake in shares of Homology Medicines in the 1st quarter valued at about $1,200,000. TD Asset Management Inc. grew its stake in shares of Homology Medicines by 15.8% in the 1st quarter. TD Asset Management Inc. now owns 27,868 shares of the company’s stock valued at $773,000 after buying an additional 3,800 shares during the period. Finally, Marshall Wace LLP acquired a new stake in shares of Homology Medicines in the 1st quarter valued at about $74,000. Hedge funds and other institutional investors own 68.09% of the company’s stock.

In related news, CFO W Bradford Smith sold 6,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $19.00, for a total value of $114,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Arthur Tzianabos sold 12,500 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $18.98, for a total transaction of $237,250.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 92,566 shares of company stock worth $1,714,997. 33.40% of the stock is owned by insiders.

Several analysts have recently commented on FIXX shares. HC Wainwright set a $36.00 target price on Homology Medicines and gave the company a “buy” rating in a research note on Tuesday, June 11th. Robert W. Baird started coverage on Homology Medicines in a research note on Monday. They issued an “outperform” rating and a $30.00 target price for the company. Canaccord Genuity set a $37.00 target price on Homology Medicines and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, Zacks Investment Research upgraded Homology Medicines from a “sell” rating to a “hold” rating in a research note on Tuesday, July 16th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Homology Medicines currently has a consensus rating of “Buy” and an average target price of $31.40.

Shares of FIXX traded down $0.75 during trading hours on Friday, hitting $19.73. The stock had a trading volume of 24,489 shares, compared to its average volume of 244,810. The firm has a 50 day simple moving average of $18.02 and a 200-day simple moving average of $21.60. The firm has a market capitalization of $954.07 million, a P/E ratio of -9.86 and a beta of 0.11. Homology Medicines Inc has a 1-year low of $14.19 and a 1-year high of $31.80.

Homology Medicines (NASDAQ:FIXX) last issued its earnings results on Thursday, August 8th. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.06). The firm had revenue of $0.39 million during the quarter, compared to analyst estimates of $1.00 million. Homology Medicines had a negative net margin of 3,232.67% and a negative return on equity of 38.74%. On average, research analysts forecast that Homology Medicines Inc will post -2.27 EPS for the current fiscal year.

Homology Medicines Company Profile

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Recommended Story: Street Name

Want to see what other hedge funds are holding FIXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Homology Medicines Inc (NASDAQ:FIXX).

Institutional Ownership by Quarter for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.